Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-165, ARCT-154, and ARCT-021 self-amplifying RNA vaccines for COVID-19
NCT05037097Phase 2Completed
- Sponsor
- Arcturus Therapeutics
- Start
- Aug 2021
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of ARCT-165, ARCT-154, ARCT-021 in coronavirus disease 2019 (COVID-19), sponsored by Arcturus Therapeutics. Started Aug 2021; status: completed.
02
Drugs
ARCT-165ARCT-154ARCT-021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05037097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037097.